Abstract

Prostate cancer is the most commonly diagnosed cancer and the second most common cause of cancer-related death in men, and benign prostatic hyperplasia is the most common benign condition known to occur in ageing men. Oestrogen has been implicated in the development of prostate cancer, and offers a promising new avenue for treatment. Despite this, the role of oestrogens in the prostate is complex. This Perspective presents a rationale for a targeted approach for the treatment of prostate disease through the use of selective oestrogen-receptor modulators in conjunction with contemporary androgen-ablation therapy.

Author affiliations

1. Stuart J. Ellem and Gail P. Risbridger are at the Centre for Urological Research, Monash Institute of Medical Research, Monash University, 27–31 Wright Street, Clayton, Victoria, 3168, Australia.

Correspondence to: Gail P. Risbridger¹ Email: Gail.Risbridger@med.monash.edu.au

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.